EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High‐Resolution Genomic Characterization of WAGR Spectrum Disorder: Insights From a Novel Cohort and Literature Synthesis, and Validation of Patient‐Reported Data

Andrew M George iD, Bamelak T Duki, Zoe S Katz, Aravind Viswanathan iD, Suzanne P MacFarland iD, Evan R Hathaway, Caitlin Monahan, John Morris, Kelly L Trout, Shari M Krantz, Arupa Ganguly, Jennifer M Kalish iD

American Journal of Medical Genetics Part A · 2026

DOI: 10.1002/ajmg.a.70159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Medical Genetics Part A, 2026. Verfasst von Andrew M George und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Genetic and Genomic Medicine, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: WAGR Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: International WAGR Syndrome Association, Miranda's Mission, WAGR Warriors.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

WAGR spectrum disorder (WAGRSD) is an ultra‐rare congenital disorder caused by heterozygous deletion of chromosome 11p13. While classically associated with Wilms tumor, Aniridia, Genitourinary anomalies, and a Range of developmental delays, accurate delineation of the deletion is critical for prognosis because the phenotypic spectrum extends well beyond this tetrad. To improve diagnostic resolution, we developed and validated a high‐density custom CGH–SNP array for precise breakpoint mapping of 11p13. We present a molecularly confirmed cohort of 23 new patients and integrate these with 91 published cases, forming the largest combined cohort to date ( N = 114) with detailed genotype–phenotype information. Key findings include: (1) the custom array provided superior genomic resolution compared to standard clinical arrays; (2) seven patients (6.1%) were found to have a dual diagnosis of WAGRSD and Potocki‐Shaffer syndrome (PSS)—a contiguous‐gene syndrome characterized by multiple osteochondromas that requires distinct surveillance; (3) in 42 patients with fully defined deletions ( n = 42, 38% of the cohort), no statistically significant association was observed between deletion of LMO2 (or other candidate genes) and Wilms tumor risk; and (4) phenotypic frequencies in this medically validated cohort closely aligned with prior caregiver‐reported registry data, validating patient‐driven registries as a reliable resource for rare disease research. Together, these findings underscore the necessity of high‐resolution genomic testing to guide counseling, refine anticipatory management—including screening for PSS‐related complications—and expand the phenotypic understanding of 11p13 deletion disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

WAGR SyndromeHumansChromosomes, Human, Pair 11FemaleComparative Genomic HybridizationMaleChromosome DeletionCohort StudiesChild, PreschoolPhenotypeGenetic Association StudiesInfantPolymorphism, Single NucleotideChildGenomicsWilms Tumor

Stichwörter der Autor:innen

11p13 deletionWAGR spectrum disorder (WAGRSD)WAGR syndromeWilms tumorhigh resolution genomic array

Autor:innen und Institutionen

  • Division of Genetic and Genomic Medicine, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Department of Pediatrics, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • International WAGR Syndrome Association, Montgomery Village, Maryland, USA.

ORCID-Profile: Andrew M George, Aravind Viswanathan, Suzanne P MacFarland, Jennifer M Kalish

Förderung

  • International WAGR Syndrome Association
  • Miranda's Mission
  • WAGR Warriors
  • Miranda Morris WAGR Spectrum Research Fund at the Children's Hospital of Philadelphia

Zitieren

APA

George, A. M., Duki, B. T., Katz, Z. S., Viswanathan, A., MacFarland, S. P., Hathaway, E. R., Monahan, C., Morris, J., Trout, K. L., Krantz, S. M., Ganguly, A., & Kalish, J. M. (2026). High‐Resolution Genomic Characterization of WAGR Spectrum Disorder: Insights From a Novel Cohort and Literature Synthesis, and Validation of Patient‐Reported Data. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.70159

Vancouver

George AM, Duki BT, Katz ZS, Viswanathan A, MacFarland SP, Hathaway ER, et al. High‐Resolution Genomic Characterization of WAGR Spectrum Disorder: Insights From a Novel Cohort and Literature Synthesis, and Validation of Patient‐Reported Data. American Journal of Medical Genetics Part A. 2026. doi:10.1002/ajmg.a.70159

BibTeX
@article{George2026,
  author = {George, Andrew M and Duki, Bamelak T and Katz, Zoe S and Viswanathan, Aravind and MacFarland, Suzanne P and Hathaway, Evan R and Monahan, Caitlin and Morris, John and Trout, Kelly L and Krantz, Shari M and Ganguly, Arupa and Kalish, Jennifer M},
  title = {High‐Resolution Genomic Characterization of WAGR Spectrum Disorder: Insights From a Novel Cohort and Literature Synthesis, and Validation of Patient‐Reported Data},
  journal = {American Journal of Medical Genetics Part A},
  year = {2026},
  doi = {10.1002/ajmg.a.70159}
}
Kostenlos starten →